Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jens Hoffmann

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
Magma (New York, N.Y.)|March 21, 2016
Volumetric imaging with homogenised excitation and static field at 9.4 TDesmond H Y Tse, Christopher J Wiggins, Dimo Ivanov, et al.
International Journal of Cancer|November 19, 2014
A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment optionKonrad Klinghammer, Jan-Dirk Raguse, Thomas Plath, et al.
International Journal of Clinical Pharmacology and Therapeutics|July 12, 2017
Animal models for personalized treatment optionsIduna Fichtner, Konrad Klinghammer, Diana Behrens, et al.
Advances in Biological Regulation|January 12, 2021
Mutation-specific effects of NRAS oncogenes in colorectal cancer cellsNatalia Kuhn, Bertram Klinger, Florian Uhlitz, et al.
Frontiers in Neurology|March 15, 2024
Establishing an MSU service in a medium-sized German urban area-clinical and economic considerationsJohann S Rink, Fabian Tollens, Andrej Tschalzev, et al.
Neoplasia (New York, N.Y.)|November 19, 2020
Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicineMaria Rivera, Iduna Fichtner, Annika Wulf-Goldenberg, et al.
Peptides|November 30, 2023
EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma modelsMicah N Sagini, Michael Zepp, Ergül Eyol, et al.
International Journal of Cancer|December 19, 2013
Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancerRoberta Schmieder, Jens Hoffmann, Michael Becker, et al.
Frontiers in Oncology|June 1, 2012
Evaluation of activity and combination strategies with the microtubule-targeting drug sagopilone in breast cancer cell linesJulia Eschenbrenner, Sebastian Winsel, Stefanie Hammer, et al.
International Journal of Cancer|January 13, 2005
Anti-tumor efficacy of the nucleoside analog 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl) cytosine (4'-thio-FAC) in human pancreatic and ovarian tumor xenograft modelsDeborah A Zajchowski, Sandra L Biroc, Hsaio-Lai Liu, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Magma (New York, N.Y.)|March 21, 2016
Volumetric imaging with homogenised excitation and static field at 9.4 TDesmond H Y Tse, Christopher J Wiggins, Dimo Ivanov, et al.
International Journal of Cancer|November 19, 2014
A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment optionKonrad Klinghammer, Jan-Dirk Raguse, Thomas Plath, et al.
International Journal of Clinical Pharmacology and Therapeutics|July 12, 2017
Animal models for personalized treatment optionsIduna Fichtner, Konrad Klinghammer, Diana Behrens, et al.
Advances in Biological Regulation|January 12, 2021
Mutation-specific effects of NRAS oncogenes in colorectal cancer cellsNatalia Kuhn, Bertram Klinger, Florian Uhlitz, et al.
Frontiers in Neurology|March 15, 2024
Establishing an MSU service in a medium-sized German urban area-clinical and economic considerationsJohann S Rink, Fabian Tollens, Andrej Tschalzev, et al.
Neoplasia (New York, N.Y.)|November 19, 2020
Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicineMaria Rivera, Iduna Fichtner, Annika Wulf-Goldenberg, et al.
Peptides|November 30, 2023
EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma modelsMicah N Sagini, Michael Zepp, Ergül Eyol, et al.
International Journal of Cancer|December 19, 2013
Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancerRoberta Schmieder, Jens Hoffmann, Michael Becker, et al.
Frontiers in Oncology|June 1, 2012
Evaluation of activity and combination strategies with the microtubule-targeting drug sagopilone in breast cancer cell linesJulia Eschenbrenner, Sebastian Winsel, Stefanie Hammer, et al.
International Journal of Cancer|January 13, 2005
Anti-tumor efficacy of the nucleoside analog 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl) cytosine (4'-thio-FAC) in human pancreatic and ovarian tumor xenograft modelsDeborah A Zajchowski, Sandra L Biroc, Hsaio-Lai Liu, et al.
Pageof 9